Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOTON: High-Dose Aflibercept in Diabetic Macular Edema
NCT04429503Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2020
- Primary completion
- May 2022
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 8
01
Overview
A Phase 3 trial of aflibercept in diabetic macular edema (DME), sponsored by Regeneron Pharmaceuticals. Started Jun 2020; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04429503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04429503.